(Press-News.org) Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups. According to the findings, such an added benefit is not proven because the dossier contained no suitable data for any of the two therapeutic indications.
G-BA specified adalimumab or infliximab as comparator therapy
Crohn disease and ulcerative colitis are chronic inflammatory bowel diseases. Vedolizumab is an option when conventional therapy is not tolerated or does not provide sufficient release of symptoms. This conventional treatment can also be a tumour necrosis factor alpha (TNFα) antagonist.
The Federal Joint Committee (G-BA) specified a TNFα antagonist (adalimumab or infliximab) as appropriate comparator therapy for both therapeutic indications. It is to be noted that it is possible to switch to a different TNFα antagonist or to adjust the dose in case of treatment failure with a TNFα Antagonist.
Drug manufacturer presented no studies for Crohn disease
In its dossier, the manufacturer identified no randomized controlled trial (RCT) that directly compared vedolizumab with adalimumab for patients with moderately to severely active Crohn disease. Since it also conducted no indirect comparisons on the basis of RCTs, an added benefit of vedolizumab for the therapeutic indication Crohn disease is not proven.
Ulcerative colitis: indirect comparison with placebo as common comparator
The dossier also contained no direct comparative RCTs on the therapeutic indication of moderately to severely active ulcerative colitis. However, the manufacturer conducted an adjusted indirect comparison. On the one hand, it used an RCT that compared vedolizumab with placebo (study C13006). On the other, it used three RCTs in which adalimumab was tested against placebo (ULTRA 1, ULTRA 2, M10-447). The placebo was used as common comparator.
Compared populations were not sufficiently similar
In principle, this approach is suitable to prove an added benefit. One important prerequisite was not fulfilled however: The compared populations of the vedolizumab and adalimumab studies were not sufficiently similar. The main reason for this was that the studies had different designs.
Both the vedolizumab study and two of the three adalimumab studies (ULTRA 2 and M10 447) had a two-phase design: an induction phase and a subsequent maintenance phase. In the vedolizumab study, however, only those patients were randomized and treated who had responded to vedolizumab in the induction phase. In the two adalimumab studies, in contrast, both responders and non-responders received continued treatment in the maintenance Phase.
Side effects were not analysed adequately
The indirect comparison was also unsuitable for a second reason: The adverse events in the vedolizumab study were not analysed adequately.
An added benefit of vedolizumab in comparison with adalimumab is therefore also not proven for patients with moderately to severely active ulcerative colitis.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
INFORMATION:
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on vedolizumab.
The G-BA website contains both general English-language information on benefit assessments pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of vedolizumab.
More English-language information will be available soon (Assessment module I, Sections I 2.1 to I 2.6, and Assessment module II, Sections II 2.1 to II 2.6, of the dossier assessment, as well as subsequently published health information on » http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.
On behalf of the Federal Ministry of Health (BMG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether specific methodological aspects have to be considered in the conduct, analysis and assessment of the certainty of results of studies on rare diseases. Within the framework of the same commission, the Institute also analysed the underlying studies for the approval of so-called orphan drugs, i.e. drugs for rare diseases, in Europe.
The result: For a different approach than in more common diseases, there are neither scientific reasons ...
Multiple pathways exist to a low greenhouse gas future, all involving increased efficiency and a dramatic shift in energy supply away from fossil fuels. A new tool 'SWITCH' enables policymakers and planners to assess the economic and environmental implications of different energy scenarios. It is presented today at the congress Global Challenges: Achieving Sustainability, hosted by the University of Copenhagen.
"SWITCH is a tool we can use to examine the different choices of technologies within the electrical power sector and their locations. It enables us to estimate ...
For teenagers, learning to establish a healthy degree of autonomy and closeness in relationships (rather than easily giving in to peer pressure) is an important task. A new longitudinal study has found one reason adolescents struggle with balancing autonomy and closeness in relationships: parents' psychological control. Teens whose parents exerted more psychological control over them when they were 13 had more problems establishing friendships and romantic relationships that balanced closeness and independence, both in adolescence and into early adulthood.
The study, ...
The lives of adolescents at home and at school may seem quite separate, but recent research has highlighted important connections. Family conflict and problems at school tend to occur together on the same day and sometimes even spill over in both directions to the next day, with family conflict increasing the likelihood of problems at school and vice versa. Now a new study has found that conflicts at home spill over to school and school problems influence problems at home up to two days later, and that negative mood and psychological symptoms are important factors in the ...
While losses in family income predict increases in behavior problems for many children, attending high-quality early childhood education and care centers offers some protection against families' economic declines, according to a new study out of Norway. In Norway, publicly subsidized high-quality early childhood education and care is available to all children, from low-income to affluent, starting at age 1. The study found that children who don't take part in such programs have more early behavior problems when their families' income drops.
The study was conducted by ...
Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the infecting microbe—may help detect invasive aspergillosis, a fungal infection that is a leading cause of mortality in patients with compromised immune systems, according to a proof-of-concept study now online in Clinical Infectious Diseases.
Currently difficult to diagnose, this type of fungal pneumonia often requires a lung biopsy for definitive ...
A rare form of a devastating disease which causes low blood sugar levels in babies and infants may now be recognised earlier thanks to a new test developed by researchers from The University of Manchester.
Congenital hyperinsulinism starves a baby's brain of blood sugar and can lead to lifelong brain damage or permanent disability according to previous research carried out by the Manchester team. The condition occurs when specialised cells in the pancreas release too much insulin which causes frequent low sugar episodes - the clinical opposite of diabetes. Treatment ...
Researchers at Queen's University Belfast have discovered that music therapy reduces depression in children and adolescents with behavioural and emotional problems.
In the largest ever study of its kind, the researchers in partnership with the Northern Ireland Music Therapy Trust, found that children who received music therapy had significantly improved self-esteem and significantly reduced depression compared with those who received treatment without music therapy.
The study, which was funded by the Big Lottery fund, also found that those who received music therapy had ...
Scientists from the University of Southampton have revealed that feather shafts are made of a multi-layered fibrous composite material, much like carbon fibre, which allows the feather to bend and twist to cope with the stresses of flight.
Since their appearance over 150 million years ago, feather shafts (rachises) have evolved to be some of the lightest, strongest and most fatigue resistant natural structures. However, relatively little work has been done on their morphology, especially from a mechanical perspective and never at the nanoscale.
The study, which is ...
ANN ARBOR, Mich. — Right out of the starting gate, Michigan's expansion of health coverage for the poor and near-poor holds lessons for other states that are still on the fence about expanding their own Medicaid programs under the Affordable Care Act, a new analysis shows.
In an article in the New England Journal of Medicine, a team of University of Michigan Medical School researchers publish the first analysis of the initial results from the Healthy Michigan Plan, which launched this past April.
In its first 100 days, the authors write, the plan enrolled 327,912 ...
